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Abstract Introduction: Recruitment for Alzheimer’s disease (AD) prevention research studies is challenging
because of lack of awareness among cognitively healthy adults coupled with the high screen fail rate
due to participants not having a genetic risk factor or biomarker evidence of the disease. Participant
recruitment registries offer one solution for efficiently and effectively identifying, characterizing, and
connecting potential eligible volunteers to studies.
Methods: Individuals aged 55-75 years who live in the United States and self-report not having a
diagnosis of cognitive impairment such as MCI or dementia are eligible to join GeneMatch. Partic-
ipants enroll online and are provided a cheek swab kit for DNA extraction and apolipoprotein E
(APOE) genotyping. Participants are not told their APOE results, although the results may be used
in part to help match participants to AD prevention studies.
Results: As of August 2018, 75,351 participants had joined GeneMatch. Nearly 30% of participants
have one APOE4 allele, and approximately 3% have two APOE4 alleles. The percentages of APOE4
heterozygotes and homozygotes are inversely associated with age (P , .001).
Discussion: GeneMatch, the first trial-independent research enrollment program designed to recruit
and refer cognitively healthy adults to AD prevention studies based in part on APOE test results, pro-
vides a novel mechanism to accelerate prescreening and enrollment for AD prevention trials.
 2019 the Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.
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1. Background
Alzheimer’s disease (AD) remains one of the greatest
medical, economic, and societal burdens in the United States
(US) and globally [1]. An estimated 5.7 million people in the
US currently have dementia due to AD—a number projected
to more than double to nearly 14 million by 2050 [2]. Inter-
ventions that delay the symptomatic onset of the disease by
even by 1 or 2 years would have a major public health impact
[3]. As a result, the National Plan toAddress Alzheimer’s Dis-
ease has set a goal of preventing AD by 2025. With a height-
ened sense of urgency, numerous AD prevention studies are
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underway, with many more planned. Unfortunately, the cur-
rent approach to recruiting participants into AD prevention
trials is lengthy, costly, and inefficient, leading some to
conclude that the field has reached a crisis point [4].
The sharp growth in AD prevention trials requires an un-
precedented screening and enrollment funnel [5]. Specifically,
researchers will need to screen tens of thousands of cogni-
tively healthy older adults to identify the thousands of individ-
uals eligible to enroll in prevention trials [6]. The number
needed to screen is further increased if AD prevention trials
require specific enrichment strategies, such as biomarker evi-
dence of AD or genetic risk for the disease. Overall, this
recruitment benchmark confronts theADfieldwith a daunting
challenge. In the US, regardless of disease area, the vast ma-
jority of studies (85%-90%) experience significant delays in
recruitment and enrollment [7]. Nearly one-third of trials
under-enroll, and only 7% meet their target enrollment num-
ber on deadline [8]. Numerous factors contribute to these dif-
ficulties. Recruitment is time consuming, sometimes taking
years to meet target sample sizes. This is in large part because
screen failure rates can reach as high as 85%, chiefly due to
inclusion criteria, such as requiring an AD biomarker or ge-
netic risk factor to enroll in an AD prevention trial [9]. De-
layed or inefficient recruitment has scientific, financial, and
ethical consequences [10]. Improving recruitment methods
has become a critical priority for the field [9,11–14].
As the number of AD prevention trials increase, there is a
growing need for mechanisms to quickly and efficiently reach
out to, identify, characterize, and refer potential participants to
trials, with the overarching goal of reducing the percentage of
individuals who screen fail. Recruitment registries are
innovative tools designed to fulfill this need. In the US, several
AD-focused registries are currently being used on both the
national and local levels, including the Alzheimer’s Prevention
Registry (APR) (www.endALZnow.org) and its predecessor
the Arizona Alzheimer’s Registry [15], the Alzheimer’s
Association’s TrialMatch program (https://trialmatch.alz.org/
find-clinical-trials), the Brain Health Registry (http://www.
brainhealthregistry.org/) [16], Cleveland Clinic’s Healthy
Brains program (https://healthybrains.org/), the University of
California-Irvine Consent-to-Contact Registry (https://c2c.uci.
edu/) [17], and the Wisconsin Registry for Alzheimer’s
Prevention [18]; this list does not include trial ready cohorts
that often have a different focus and objective [19–21] or
registries for autosomal dominant AD [22]. Each of these
recruitment registries approaches participant recruitment and
engagement differently, and the field is still gathering data on
best practices for the design and conduct of recruitment
registries [14]. Some registries have begun to try to identify
participants who are at elevated risk for symptomatic onset of
AD, either based on change in cognition, biomarker
evidence of the disease, or genetics, for eventual referral into
AD prevention studies. For example, the Alzheimer’s
Prevention Initiative (API) Generation Program is enrolling
adults aged 60-75 years with one or two copies of the APOE4
gene [23,24], given that the APOE ε4 allele is associated with
an increased risk of dementia due to AD in later life and
younger age of onset of symptoms [25,26].
Here, we describe the design and execution of, as well as
enrollment metrics, participant demographics and key les-
sons learned from GeneMatch, a program of the APR and
API, developed as a trial-independent recruitment registry
to match individuals to AD prevention studies based in
part on their APOE genotype. Although most studies
perform APOE genotyping as part of screening to determine
eligibility, GeneMatch was created as a trial-independent
program that (1) enables genetic information to be stored
outside of a specific trial and (2) allows for participant re-
contact for a variety of studies for which they might be
eligible, rather than just one trial.
2. Methods
In 2012, before the development of GeneMatch, Banner
Alzheimer’s Institute launched the APR (NCT02022943;
www.endALZnow.org) as an online resource to connect indi-
viduals to AD-related studies taking place in their commu-
nities. APR members provide minimal contact and
demographic information at signup and opt in to receiving
monthly newsletters on the latest AD research as well as no-
tifications when study opportunities are available in their
community; approximately 320,000 have joined APR as of
August 2018. In 2015, the APR platform was expanded to
include GeneMatch (NCT02564692; https://www.
endalznow.org/genematch). GeneMatch allows for online
sign-up, consent, and submission of identifiable information
while providing technical and physical safeguards of the data.
2.1. GeneMatch enrollment
Individuals aged 55-75 years, who live in the US (50
states and District of Columbia), and self-report not having
a diagnosis of a cognitive impairment such as MCI or de-
mentia are eligible to join GeneMatch. Individuals can enroll
remotely or in person at one of 37 GeneMatch partner
healthcare sites in 24 states.
All participants, whether they are enrolling remotely or at
a partner site, complete the GeneMatch enrollment process
via the program’s website www.endALZnow.org/gene
match. Enrollment consists of five steps: learning about
the program (education module), creating an account,
providing consent and Health Insurance Portability and
Accountability Act of 1996 (HIPAA) authorization,
providing contact and demographic information, and con-
firming account information for enrollment. The education
module provides information about AD, the APOE gene
and associated risk of developing MCI or dementia due to
AD, and an overview of the GeneMatch program. During
this process, participants learn that GeneMatch does not
disclose APOE test results to them directly, but those results
may be used in part to help match them to research studies,
which may in turn require participants to learn their test
J.B. Langbaum et al. / Alzheimer’s & Dementia 15 (2019) 515-524516
results as part of enrollment into a given study. Following the
education module, individuals are prompted to answer five
questions to reinforce the key learning concepts presented
during the module (Table 1). Individuals are not required
to answer the questions correctly to proceed with enroll-
ment, and all individuals are shown the correct response
regardless of how they answered the question. Next, partic-
ipants provide the following information: name, mailing and
email addresses, phone number, date of birth, and biological
sex at birth; information about family history of AD and
race/ethnicity are optional. Participants can log in to their ac-
count at any time to update their information.
2.2. APOE genotyping
After enrollment and consent, participants are either
mailed a cheek swab kit to their homes for DNA collection
or handed a kit if enrollment is done at a partner site. The
kit includes detailed instructions and pictures describing
how to use the swab, with abbreviated instructions printed
on the kit box. Participants are instructed to not eat or drink
anything other than water for 1 hour before swabbing the in-
side of their cheek with the buccal swab. After the swab
dries, participants close the swab tube and place the swab
and laboratory requisition form in the addressed and
postage-paid envelope for return to the laboratory for DNA
extraction and APOE genotyping. The laboratory is
accredited by the College of American Pathologists and
certified through Clinical Laboratory Improvement Amend-
ments. As an additional level of quality assurance, all sam-
ples include sex verification, which is cross-checked
against the information provided at enrollment and on the
laboratory requisition form. APOE results are stored on a
HIPAA-compliant server, separate from other demographic
information. All DNA samples are destroyed after APOE
genotyping. In instances in which APOE genotyping and
sex verification cannot be completed due to poor DNAyield,
or sex verification results are discordant with self-reported
genetic sex, participants are notified via email and are sent
a new cheek swab kit to complete.
2.3. Timing of the education model
GeneMatch launched a beta version in November 2015 to
fine-tune the enrollment process. In the beta version, all
interested individuals were required to first create an account
enrolling in the program before completing the other enroll-
ment steps (Fig. 1). Based on unsolicited feedback submitted
to the study team via email, phone, and social media chan-
nels from prospective volunteers, as well as the need to
Table 1
Education module quiz questions and response rates




1. The common form of Alzheimer’s




 I don’t know
89.1%
2. How does having the APOE e4 gene
affect the chances that someone will
get Alzheimer’s disease?
 It increases the chance of getting
Alzheimer’s disease
 It decreases the chance of getting
Alzheimer’s disease
 It has no effect on the chance of getting
Alzheimer’s disease
 It guarantees Alzheimer’s disease
 I don’t know
80.5%
3. Can the APOE genetic test predict
with certainty whether or not someone
will get Alzheimer’s disease?
 Yes
 No
 I don’t know
89.1%
4. I will learn my APOE test results





 I don’t know
70.7%
5. GeneMatch will use my APOE test
results to match mewith studies which
may or may not require me to learn my
APOE test results. It is my choice to
pursue these research opportunities.
 True
 False
 I don’t know
85.9%
Abbreviation: APOE, apolipoprotein E.
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ensure that prospective participants are fully briefed on the
program before creating an account, the enrollment flow
was modified, and the final version was launched in
November 2016. In the final version, individuals are first pre-
sented with the education module in both video and bulleted
text format and then answer the five-question assessment
before they are prompted to create an account and complete
the remaining enrollment steps (Fig. 1).
2.4. GeneMatch partner healthcare sites
As noted previously, GeneMatch currently has 37 partner
healthcare sites in 24 states; new partner sites are added on
an ongoing basis. GeneMatch launched its partner site pro-
gram in July 2016 after receiving anecdotal feedback during
the beta version that researchers and physicians who regu-
larly hold community events as part of their recruitment
and outreach strategy wanted a way to enroll interested indi-
viduals into GeneMatch without requiring participants to
wait 1 to 2 weeks to receive their cheek swab kits in the
mail. Partner sites can enroll participants on site (though
all enrollment steps, including consent, are still completed
via the GeneMatch website) and have site staff distribute
the cheek swab kits rather than having the kit mailed to
participants’ homes. Partner sites must cede Institutional
Review Board review to the GeneMatch Institutional
Review Board because consent is done online and there is
only one informed consent document.
2.5. Participant recruitment
Several recruitment strategies and tactics are used to
enroll participants into GeneMatch, including community
talks, flyers, regionally tailored postcards mailed to prospec-
tive volunteers, billboards, social media advertisements, and
earned media coverage. In October 2017, a social media
advertising campaign was launched to raise awareness about
the GeneMatch program to men because men are underrep-
resented in the program.
2.6. Participant retention and engagement
Following enrollment, participants receive periodic up-
dates via email from GeneMatch (e.g., when their kit orders
are received, when the kits are mailed to their homes, when
their completed kits are received by the laboratory, and for
general GeneMatch program information). In addition, Gen-
eMatch participants opt in to receive monthly email newslet-
ters from the APR to keep them informed about the latest
research on AD. Participants are notified by email, and in
Fig. 1. GeneMatch enrollment process. Abbreviation: HIPAA, Health Insurance Portability and Accountability Act of 1996.
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some cases, by postal mail, when they have been matched to
studies and are provided instructions should they be inter-
ested in learning more about a study or enrolling.
2.7. Ethical considerations
GeneMatch enrollment criteria require participants to
self-identify as not having a diagnosis of cognitive impair-
ment such as MCI or dementia due to AD because one of
the main objectives of the GeneMatch program is to match
participants to AD prevention trials based in part on their
APOE genotype. Moreover, enrollment and consent are
done online, thus limiting our ability to assess capacity for
understanding in individuals with a diagnosis of cognitive
impairment.We acknowledge that it is possible that some in-
dividuals with cognitive impairment join GeneMatch
because we do not assess participants’ cognitive function
beyond what is required to navigate the GeneMatch website
and complete the multistep enrollment process. Nonetheless,
online enrollment and consent are deemed appropriate given
the minimal risks to participants.
The education module serves to reinforce key aspects of
the GeneMatch program, something particularly important
because consent is done online. The module includes infor-
mation about AD, the APOE gene, and associated risk of
developing MCI or dementia due to AD. These concepts
are reinforced in the five-question quiz immediately after
the education module and again in the consent document.
These components help ensure participants are well
informed before they provide a sample of DNA.
GeneMatch does not disclose APOE test results to partici-
pants,althoughstudies towhichparticipantsmatchmaydisclose
results as part of the study’s enrollment and screening process.
Disclosure of genetic information is the practice of medicine
and requires specific guidelines to be followed, includingwork-
ingwith agenetic counselororother licensedhealth careprofes-
sional (regulations vary from state to state) [27].
GeneMatch is a trial-independent recruitment registry and
works directly with study sponsors and researchers to develop
the selection criteria or algorithm based on the unique needs
of each study. For example, a study sponsormaywish to invite
a ratio ofAPOE4 carriers to noncarriers aged 65-75 years who
live within a 100-mile radius of study sites. Its standard oper-
ating procedures require GeneMatch to make participants
aware of all study opportunities to which they have been
matched. If a participant has been matched to more than
one study, participants have the choice to pursue the study
that is of interest to them (or decline both studies). Gene-
Match does not reserve participants with specificAPOE geno-
types for specific studies, nor does GeneMatch choose which
studies take priority in access to its participants.
2.8. Data analyses
A Z-test for two proportions was used to examine swab
return rate data by year and swab return rate by enrollment
source. In addition, because enrollment into GeneMatch re-
quires participants to self-identify as not having a diagnosis
of cognitive impairment and the 34 variant of APOE is asso-
ciated with a younger age of onset of symptoms, a Z-test for
two proportions was used to examine APOE genotype re-
sults by age group. All analyses were conducted using Med-
Calc 17.9.7.
3. Results
3.1. Participant recruitment, enrollment, and
characteristics
As of August 2018, 75,351 participants had enrolled in
GeneMatch. Participant demographic characteristics and
recruitment sources are shown in Table 2. Participants
have a mean age of 65.0 (SD 5.4) years and are predomi-
nately female (69%). Over half of participants (60%) joined
GeneMatch via social media advertisements. A sizable pro-
portion of participants (79%) opted to receive email newslet-
ters from the APR. From November 2015 until October
2017, 21% of GeneMatch enrollees were men. From
October 2017, when a social media campaign to raise aware-
ness of the GeneMatch program to men was launched, until
August 2018, 44% of GeneMatch enrollees were men, which
represented a statistically significant increase from the
November 2015 to October 2017 recruitment period
(P , .001).
3.2. GeneMatch enrollment based on timing of education
module
GeneMatch enrollment rates were compared before and
after moving the education module relative to account
Table 2
Demographic characteristics of GeneMatch participants (n 5 75,351)
Age, mean (standard deviation) 65.0 (5.4)
Sex, female 69%





Prefer not to answer 32%
Race/ethnicity*
Non-Hispanic, white 63.9%




Prefer not to answer 28.8%
Recruitment/enrollment source




Online or social media 60.0%
Partner healthcare site 6.4%
Other 4.1%
*Participants are able to select multiple options, only those reported by
0.3% or more of participants are listed.
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creation (Table 3). Nearly all participants (90%) who
watched the education video or reviewed the bulleted text
completed the post–education quiz. Response rates to the ed-
ucation questions are displayed in Table 1. In the beta
version, 40% of people who reviewed and confirmed they
met GeneMatch eligibility criteria continued through the
entire process to complete their enrollment and registration.
In the final version, 49% of people completed their enroll-
ment and registration. Continuation rates after creating the
account were also improved from the beta version (79%
vs. 85%). Finally, the cumulative percentage of participants
who completed enrollment and registration after creating an
account was 62% in the beta version compared with 91% in
the final version.
3.3. Cheek swab return
Most participants returned their completed cheek swabs
within 90 days, although the return rate varied across the
3 years, with 76% of participants who joined in 2015
returning their swabs within 90 days compared with 68%
of those who enrolled in 2016 and 74% in 2017 (2015 vs.
2016, P , .001; 2016 vs. 2017, P , .001; 2015 vs. 2017,
P 5 .12). Examining swab return by GeneMatch
recruitment/enrollment source, the highest swab return
percentage was among individuals enrolling through a
partner healthcare site (93.6%). A high swab return was
demonstrated among people registering directly through
the GeneMatch website, such as via organic traffic to the
website or through email outreach directing people to the
website (83.1%); 78.9% of those who registered for
GeneMatch by first enrolling in the APR returned their
completed swab. The swab return rate for individuals
directed to GeneMatch through social media advertisements
was lower than other registration sources (64.0%). The
partner site return rate (93.6%) was significantly higher
than all other enrollment sources (P , .001 for all
between-source comparisons).
3.4. APOE genotype results
Participants’ APOE genotypes are presented in Table 4.
Consistent with genotype prevalence reported in the litera-
ture [28], over half of participants (56%) have the APOE
3 / 3 genotype, whereas approximately 3% have the
APOE 34/ 34 genotype. The APOE 3 / 34 and 34/ 34 genotypes
are more prevalent among the younger age groups ( 3 / 34 55-
59 years5 29.54%, 3 / 34 70-75 years5 23.64%, P, .001;
34/ 34 55-59 years 5 4.08%, 34/ 34 70-75 years 5 2.20%,
P, .001), likely the result of the enrollment criteria because
the ε4 allele is associated with an increased risk of dementia
due to AD and younger age of onset [25,26].
3.5. Barriers to enrollment
Anecdotal feedback submitted to the study team via
email, phone, and social media from prospective participants
suggests common themes of concerns for participating in
GeneMatch. One frequently cited theme relates to enroll-
ment in an internet-based program because of risks
regarding loss of privacy and confidentiality, particularly
in the era of data and security breaches. To help address these
concerns and provide credibility to the program, the Gene-
Match program received a Certificate of Confidentiality
from the National Institutes of Health and updated the pro-
gram website in 2018 to more prominently feature the
Table 3
GeneMatch enrollment funnel comparison: Before and after moving education module relative to account creation*
Enrollment step % Continued % Drop-off
Cumulative % continued from
“review eligibility criteria”
Cumulative % continued from after
“create account” completed
Beta enrollment process
1. GeneMatch landing page 61 39 – –
2. Review GeneMatch eligibility criteria 82 18 100 –
3. Create account 79 21 82 –
4. View education module and complete 5-question quiz 75 25 65 100
5. Review consent 88 12 49 75
6. Provide contact information 97 3 43 66
7. Review information 96 4 42 64
8. Registration complete – – 40 62
Final enrollment process
1. GeneMatch landing page 37 63 – –
2. View education module 69 31 100 –
3. Complete 5-question quiz 90 10 69 –
4. Create account 85 15 63 –
5. Review consent 92 8 53 100
6. Provide contact information 97 3 49 92
7. Review information 102y -2 48 89
8. Registration complete – 49 91
*Step 1 unique pageviews are not comparable across before versus after time periods due to changes in measurement. Therefore, the before versus after com-
parison focuses on % continuation and % drop-off.
yThe number exceeds 100% because individuals can complete the enrollment process over multiple visits to the GeneMatch website.
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academic, nonprofit organization leading the program (Ban-
ner Alzheimer’s Institute) as well as the program funders.
Another theme centered around implications of the genetic
results: for instance, if the results could be used as evidence
of a preexisting condition or as a rationale for denial of
health care insurance. To try to address these concerns, the
GeneMatch program website was updated in 2018 to feature
a “Frequently Asked Questions” (FAQ) section, including
information about the Genetic Information Nondiscrimina-
tion Act (GINA). Another theme centered around partici-
pants’ requests to receive genetic test results directly from
GeneMatch. To address this concern, the FAQ section was
updated to include information to educate prospective par-
ticipants that APOE disclosure is not a standard practice of
medicine in the US, nor are the results medically actionable.
4. Discussion
Globally, several national and local AD recruitment reg-
istries exist [16–18,20,22,29,30], but, to our knowledge,
GeneMatch is the first trial-independent program designed
to recruit and connect community-dwelling adults to AD
prevention studies based in part on APOE test results,
providing a novel mechanism to accelerate prescreening
and enrollment for AD prevention trials. Although still early
in its development, GeneMatch has produced initial evi-
dence that individuals are willing and able to participate in
a primarily internet-based recruitment registry that requires
participants to complete a cheek swab for APOE genotyping.
Although participants are not told their APOE test results,
this information is used in part to match them to AD preven-
tion studies. Invitations to studies are done in a manner that
does not inadvertently disclose genetic results to partici-
pants; for example, study invitations may be sent to geneti-
cally eligible individuals and a pragmatic ratio of genetically
ineligible individuals. Because GeneMatch is independent
from trial programs, participants are able to be re-
contacted for a variety of AD prevention-related studies
ranging from clinical trials to observational studies, a prac-
tice that was modeled after the API Colombia Registry
[22]. Moreover, GeneMatch is able to refer participants to
studies enriching based on AD risk factors other than
APOE4, such as elevated brain amyloid, because APOE4
is associated with a greater risk for elevated brain amyloid
and younger age at onset [31].
Based on the anecdotal feedback received during the beta
phase, the order of the enrollment steps was changed, moving
the education module step to before account creation. This
modification resulted in an improvement in the enrollment
and drop-off rates. The rationale for establishing partner
healthcare sites was also resulted from anecdotal feedback
during the beta phase. Over time, the partner site model has
evolved, for example, modifying email communications and
study invitations sent to participants who enrolled at a partner
healthcare site to explicitly remind them where they joined
GeneMatch. It is important to note that in both cases the anec-
dotal feedbackwas not collected systematically and as a result
reflects only a subset of attitudes toward GeneMatch. The
goal of the personalized emails is to reinforce the connection
and relationship established between the GeneMatch partici-
pant and the partner site.
GeneMatch has used a variety of recruitment strategies
and tactics to enroll participants, such as community talks,
re-contacting databases of prospective volunteers by mail
or email, and social media advertisements. Social media
advertisements have resulted in the greatest number of
enrollees, although these individuals have a slightly lower
swab return rate compared with those recruited from other
sources. Future work will examine whether source of initial
enrollment into GeneMatch is a factor in participants’
acceptance rates of their study invitations as well as the
return on investment for the different recruitment strategies
and tactics.
The overall percentages of APOE4 heterozygotes (APOE
3 / 34 and 32/ 34) and homozygotes (APOE 34/ 34) are consis-
tent with previously reported prevalence estimates (28),
although the percentages are higher in the younger age
groups. This difference is likely the result of the GeneMatch
inclusion criteria because participants must self-report not
having a diagnosis of cognitive impairment and the 34
variant of APOE is a risk factor for MCI and dementia due
to AD and a younger age of onset of symptoms [25,26].
Despite using a variety of recruitment strategies and tac-
tics, GeneMatch participants are predominantly female and
self-report being of non-Hispanic white race/ethnicity,




% of all GeneMatch
participants
% by Age at enrollment
55-59 years 60-64 years 65-69 years 70-75 years
32/ 32 0.5 0.4 0.4 0.5 0.5
32/ 3 10.2 9.6 10.1 10.6 11.2
32/ 34 2.3 2.9 2.6 2.7 2.8
3 / 3 56.4 53.4 55.6 57.7 59.6
3 / 34 26.9 29.5 27.8 25.5 23.6
34/ 34 3.3 4.1 3.5 2.9 2.2
Abbreviation: APOE, apolipoprotein E.
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registries [16]. To address this gender disparity, social media
advertisements targeting men were launched in October
2017, and although the percentage of men enrolled has
increased, more needs to be done to better understand the
barriers and facilitators to enrollment for men. Similarly, a
concerted effort is needed to address the lack of racial and
ethnic diversity among GeneMatch participants, including
understanding why a sizable percentage prefer not to provide
their race/ethnicity during initial enrollment, perhaps adapt-
ing strategies found to be effective at a local level to online
registries [32–34]. However, it is important to note that,
although other groups have been successful in increasing
enrollment of individuals from traditionally
underrepresented racial and ethnic groups into their
registries, these efforts did not translate to a high rate of
enrollment into an AD prevention study [30]. Identification
and removal of these potential barriers, as well as implemen-
tation of new recruitment solutions, are critically important
to meet the goal of enrolling diverse populations into AD
prevention trials [35].
We acknowledge several limitations of GeneMatch. For
instance, participants are not representative of the general
population. All participants, including those who join at a
partner healthcare site, must have an email address to enroll
in GeneMatch. This requirement is a potential barrier for in-
dividuals who do not have access to or use email on a routine
basis. GeneMatch participants are not representative of the
general population with regard to gender, race, or socioeco-
nomic status, although such bias is similar to what is
observed in healthy controls/cohorts enrolled in AD obser-
vational studies and is reflective of reported demographic
characteristics of participants enrolled in AD prevention tri-
als. As discussed previously, it is important for GeneMatch
to try to increase the enrollment of men and individuals
from underrepresented racial/ethnic populations to help
meet the goal of increasing diversity among participants
enrolled in AD trials [35,36]. GeneMatch does not assess
participants’ cognitive functioning, and as a result, some
participants with a diagnosis of cognitive impairment may
have joined GeneMatch, and some participants who did
not have a diagnosis at the time of enrollment may indeed
be impaired when they are matched to a study. For these
and other reasons, GeneMatch encourages participants to
review study inclusion criteria when they have been
matched to a study and emphasizes to study sites the
importance of prescreening GeneMatch referrals.
Regarding the GeneMatch program itself, we did not
conduct focus groups during the beta version. Feedback
from individuals was unsolicited and not collected in a
systematic manner, nor was a qualitative assessment
conducted. As a result, the barriers to enrollment described
previously may only reflect a subset of attitudes toward
GeneMatch. Finally, it remains unknown whether
GeneMatch accelerates enrollment into AD prevention
trials and reduces the screen fail rate. Currently, two AD
prevention trials and two observational studies are using
GeneMatch as a recruitment tool. We will report the
findings in a future publication when these studies
complete their enrollment.
4.1. Future Directions
We aim to have numerous studies use GeneMatch as a
recruitment tool, including studies enriching for risk factors
other than (or in addition to) APOE4, such as elevated brain
amyloid. The eligibility age range for GeneMatch was
selected to maximize resources and ensure as many partici-
pants as possible are matched with a study opportunity. If,
in the future, new AD preventions studies become available
for people outside of the current age range, then the program
may be adapted accordingly. Owing to consent requirements
and to minimize costs, GeneMatch only tests for APOE and
all DNA samples are destroyed after genotyping. If, in the
future, there is another genetic marker of interest that would
be used for accelerating enrollment into AD prevention
studies, GeneMatch may attempt to re-contact all partici-
pants, obtain consent, and collect new DNA samples for ge-
netic testing. A concerted effort was made when designing
GeneMatch to ensure that it was compliant with State law
for collection ofDNAand laboratory analysis. If laws change,
GeneMatch may need to adapt accordingly. Similarly, Gene-
Matchmay, in the future, need to adapt and offer disclosure of
APOE results; research studies in which genetic risk disclo-
sure protocols have been developed may provide guidance
[37]. Separate efforts are underway via several ancillary
studies to GeneMatch and theAPI Generation Program to un-
derstand (1) the shorter- and longer-term psychological and
emotional impact of APOE disclosure as part of screening
for the API Generation Program [23], (2) whether disclosure
of APOE results is associated with worsening of subjective
and objective cognitive functioning, and (3) how to design
efficient, scalable models for delivery of APOE results [38].
5. Conclusion
With the growing number of current and planned AD pre-
vention studies, it is increasingly important to have efficient
mechanisms accelerate participant enrollment into trials and
reduce the screen fail rate. Current processes are generally
inefficient, contributing to the expense and duration of trials.
In the US, recent reviews show that 85%-90% of all studies,
not just those focused on AD, have delays in recruitment and
enrollment [7], with 30% under-enrolling and only 7% of sites
enrolling the projected number of participants in their origi-
nally stated timelines (8). Despite its limitations, GeneMatch
has demonstrated that it is feasible to enroll tens of thousands
of adults across the US into a predominantly online, trial-
independent genetic recruitment registry. Most enrollees com-
plete their cheek swabs at home and return them to the labora-
tory for genetic testing. Importantly, GeneMatch does not
return APOE test results to participants. Althoughwe are opti-
mistic that GeneMatch will be an effective resource for effi-
ciently referring potential participants to AD prevention
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studies and reducing screen fail rates, we do not yet have the
data necessary to confirm this. Future publications will report
on the effectiveness of GeneMatch for accelerating recruit-
ment and enrollment into AD prevention trials.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture by traditional sources (PubMed), meeting ab-
stracts, and presentations and had personal
communication with researchers. The relevant
research on Alzheimer’s participant recruitment reg-
istries is appropriately cited.
2. Interpretation: GeneMatch has enrolled over 75,000
participants since its inception. Approximately 3%
of enrollees are APOE4 homozygotes, and the per-
centage of APOE4 carriers is inversely associated
with age. The program has demonstrated the feasi-
bility of an online recruitment registry incorporating
APOE genotyping to accelerate prescreening and
enrollment for Alzheimer’s prevention studies.
3. Future directions: Continue to enroll new partici-
pants to provide an even larger pool of prospective
volunteers for Alzheimer’s prevention studies, bring
on new study opportunities to offer GeneMatch par-
ticipants, report on the effectiveness of GeneMatch
for accelerating recruitment and enrollment into Alz-
heimer’s prevention studies, and study the barriers to
and motivators of joining a recruitment registry such
as GeneMatch to help address the lack of diversity
among participants.
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